Trials / Sponsors / Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc.
Industry · 5 registered clinical trials.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Completed | A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects with Neovascular Age-related Ma Neovascular Age-related Macular Degeneration, Age-Related Macular Degeneration, Wet Macular Degeneration | Phase 3 | 2024-01-24 |
| Active Not Recruiting | A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual I Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration | Phase 3 | 2021-11-15 |
| Completed | A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration | Phase 3 | 2020-10-01 |
| Completed | A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age- Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration | Phase 3 | 2019-06-25 |
| Completed | A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age- Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration | Phase 3 | 2018-10-01 |